Uterine Fibroids in Black Women: Causes, Symptoms, Treatment, and the Evidence

By age 50, more than 80 percent of Black women have uterine fibroids, compared with nearly 70 percent of white women, per Baird and colleagues, American Journal of Obstetrics and Gynecology 2003 (PMID 12548202). Black women develop fibroids earlier, experience more severe symptoms on average, and are 2 to 3 times more likely to be offered hysterectomy as the first-line surgical treatment. Those three facts shape the rest of what this page covers. This hub is our cornerstone synthesis: what fibroids are, what the evidence supports about cause and treatment, where the Black-specific disparities sit inside the clinical data, and the specific questions that change a fibroid care conversation with an OB-GYN. Supporting articles on each treatment, each decision point, and each fertility question are linked inline.

Uterine fibroids (leiomyomas or myomas) are benign tumors of the smooth muscle of the uterus. They are estrogen- and progesterone-responsive, which is why they grow during the reproductive years and typically shrink after menopause. They range from pea-sized to the size of a grapefruit. Most women with fibroids have more than one. The most common symptoms are heavy or prolonged menstrual bleeding, pelvic pressure or pain, bladder pressure, and, in some cases, fertility and pregnancy complications. Up to half of women with fibroids have no symptoms at all; the tumor is found on a pelvic exam or ultrasound done for a different reason.

For the symptom side specifically, our companion piece at `/articles/fibroid-symptoms-normal-vs-abnormal-2026/` unpacks the differential between fibroid-driven heavy bleeding and other causes of menorrhagia, including what clinical signs should trigger a same-day call to your OB versus what can wait for a scheduled visit.

Fibroids overlap in presentation with endometriosis. Both cause heavy bleeding, pelvic pain, and fertility complications. The diagnostic distinction matters because the treatment paths diverge. Our piece at `/articles/fibroids-vs-endometriosis-how-to-tell-the-difference-2026/` covers the differential and the imaging + clinical signs that distinguish them.

The strongest evidence on Black-versus-white prevalence and symptom severity is the Baird 2003 AJOG cumulative-incidence study, which used pelvic ultrasound to screen 1,364 randomly selected women in the Washington DC area. The study reported cumulative incidence by age 50 above 80 percent for Black women and nearly 70 percent for white women, with Black women developing fibroids at significantly earlier ages (odds ratio 2.9 for earlier onset). The paper's methodology (ultrasound-based detection rather than self-report) matters because self-reported fibroid prevalence systematically undercounts asymptomatic cases, and the undercount is larger in populations with less-regular access to gynecologic imaging.

The biological mechanisms underlying the higher Black prevalence are not fully settled in the literature. Candidate mechanisms documented in peer-reviewed work include greater estrogen exposure across reproductive life, differences in vitamin D status (fibroid growth is inversely correlated with serum 25-hydroxyvitamin D levels, and Black Americans are more likely to have low levels), genetic variants more common in African ancestry, and chronic environmental exposures including some hair-care products. The hair-care-product pathway is one of the more contested literatures: the Bertrand 2023 Black Women's Health Study (PMID 37821068) and the Sister Study findings suggest an association between frequent chemical-relaxer use and uterine-cancer risk, with fibroid-related literature carrying a weaker but still-reported association.

No single biological factor explains the full prevalence gap. The honest framing is that Black women carry a meaningfully higher fibroid burden at younger ages with more severe symptoms, and the combination of biological, environmental, and health-care-access factors compounds into the outcome disparities the next section describes.

Our live reporting at `/articles/fibroids-black-women-burden-treatment/` covers prevalence and treatment overview in full. This hub synthesizes across that piece and the supporting cluster below.

Fibroid treatment is driven by three factors: symptom severity, fertility goals, and fibroid size and location. The peer-reviewed treatment menu runs from watch-and-wait through medical therapy, uterus-preserving procedures, and hysterectomy. The honest headline is that most women with symptomatic fibroids have uterus-preserving options. Black women are more likely to be routed to hysterectomy first, and less likely to be offered the minimally invasive alternatives that have comparable efficacy for many presentations.

### Watch and wait

For women with small, asymptomatic fibroids, no treatment is often the right answer. Fibroids typically shrink after menopause, and the symptom burden of monitoring is lower than the symptom burden of treatment for many patients. Our companion piece at `/articles/do-fibroids-go-away-without-surgery-2026/` covers the watch-and-wait literature, the role of hormonal therapy in symptom control, and the specific clinical triggers that move a patient from watch-and-wait to active treatment.

### Medical therapy

Hormonal suppression is the main non-surgical treatment axis. Combined oral contraceptives reduce menstrual blood loss. GnRH antagonists including elagolix and the relugolix-combination therapy studied in the LIBERTY 1 and LIBERTY 2 trials (Al-Hendy et al., NEJM 2021, PMID 33596357) produce substantial reductions in menstrual blood loss; roughly 71 to 73 percent of participants achieved the primary endpoint of reducing menstrual blood loss below 80 ml with at least a 50 percent reduction from baseline, versus 15 to 19 percent on placebo. Medical therapy does not eliminate the fibroids; it controls the bleeding and shrinks them modestly. For women whose primary concern is heavy bleeding and who are not seeking pregnancy, medical therapy can be a durable option.

### Uterine fibroid embolization (UFE)

UFE is a minimally invasive procedure performed by interventional radiologists. A catheter threaded through the femoral or radial artery delivers small particles to block the blood supply feeding the fibroid, which causes the fibroid to shrink over the following months. UFE preserves the uterus and is typically outpatient. Recovery time is measured in days to a couple of weeks.

Head-to-head randomized data comparing UFE to surgical alternatives include the EMMY trial and subsequent comparative-effectiveness studies. UFE produces high rates of symptom improvement with lower perioperative morbidity than hysterectomy. Fertility outcomes after UFE are a nuanced question we take up in the dedicated piece at `/articles/uterine-fibroid-embolization-ufe-recovery-risks-benefits-2026/`, and the day-by-day recovery comparison is covered at `/articles/ufe-recovery-time-vs-surgery-comparison-2026/`.

### Myomectomy

Myomectomy is the surgical removal of fibroids with uterine preservation. It can be performed via open laparotomy, laparoscopy, robotic assistance, or hysteroscopy, depending on fibroid size, number, and location. For women with fertility goals, myomectomy is typically the surgical option of choice.

Black women are offered myomectomy at significantly lower rates than white women with comparable clinical presentations, and when Black women do undergo myomectomy the complication rate runs higher. The treatment-disparity evidence across hysterectomy and myomectomy is covered in the dedicated piece at `/articles/fibroids-black-women-hysterectomy-myomectomy-disparity-2026/`, which reports the 2 to 3x hysterectomy-rate disparity, the 7x myomectomy relative-risk finding from Jacoby 2010 (PMID 20430357), and the Wegienka 2017 systematic review of racial disparities in surgical outcomes.

### Hysterectomy

Hysterectomy is the definitive treatment for fibroids: complete removal of the uterus eliminates the fibroids and their symptoms permanently. It is also irreversible, and for women who have not completed childbearing, it is not a fertility-preserving option. For women with severe symptoms, multiple failed non-surgical treatments, or coexisting conditions that make uterine preservation clinically unreasonable, hysterectomy is a defensible choice.

Our editorial position is that hysterectomy should be the last option considered for fibroid treatment rather than the first. The evidence on racial disparity in route-to-hysterectomy is clear: Black women are more likely to undergo hysterectomy for fibroids via open abdominal surgery rather than the less-invasive vaginal or laparoscopic routes, with higher complication rates and longer recovery times. The reasons include provider-bias research documented in the literature, delayed diagnosis leading to larger fibroid burden at the time of surgery, and insurance-coverage differentials across minimally invasive procedures.

Fibroids and fertility is a distinct conversation that the supporting piece at `/articles/fibroids-and-fertility-what-to-know-2026/` covers in full. The headline findings:

Fibroids can reduce fertility when they distort the uterine cavity (submucosal fibroids) or block the fallopian tubes. Intramural and subserosal fibroids affect fertility less clearly. Myomectomy can restore fertility in women whose submucosal fibroids are interfering with conception, with the caveat that the recovery period before attempting pregnancy is typically 3 to 6 months.

During pregnancy, fibroids can grow rapidly because of the estrogen surge, and complications including preterm labor, fetal malposition, and increased cesarean rate are documented. Most women with fibroids have uncomplicated pregnancies; the risk profile shifts when fibroids are large, multiple, or in specific anatomic positions.

For Black women specifically, the combination of earlier fibroid onset, higher severity, and the maternal-health disparities covered in our companion hub at `/hubs/black-maternal-health/` means that prenatal care for Black women with fibroids warrants a specifically-attentive care plan.

Our dedicated piece at `/articles/questions-to-ask-doctor-about-fibroids-2026/` lists 10 specific questions. The five most important:

1. "What size are my fibroids, how many are there, and where are they located?" The answer determines which treatments are on the table. Submucosal, intramural, and subserosal fibroids have different treatment pathways.

2. "What are all my treatment options, including uterus-preserving options?" If the conversation opens with hysterectomy as the default, ask for the full menu: watch-and-wait, medical therapy, UFE, myomectomy, and hysterectomy. If the uterus-preserving options are not mentioned, ask why.

3. "What is your personal volume on myomectomy and UFE referrals?" Interventional radiologists perform UFE; gynecologic surgeons perform myomectomy. If your OB-GYN has not performed a myomectomy in the past year, a referral to a surgeon who has is a reasonable ask. The Wegienka 2017 systematic review documents outcome-volume relationships for minimally invasive routes.

4. "What are the clinical criteria for escalating from watch-and-wait to treatment?" Severity of bleeding, iron-deficiency anemia, pain interfering with daily function, and fertility timing are the standard triggers. Knowing yours in advance lets you track your own trajectory.

5. "If I want to preserve fertility, what is your treatment sequence recommendation?" The answer should name specific medical therapies and the myomectomy option, not default to hysterectomy.

The blackhealth.org directory lists verified Black OB-GYNs. Our piece at `/articles/find-a-black-ob-gyn-near-you/` (shipping sprint 2) covers the specialty-specific search and the first-visit questions. The National Medical Association Find a Doctor tool and the Association of Black Cardiologists maintain additional specialty directories. For fibroid-specific surgical care, asking any OB-GYN candidate about their myomectomy volume and their UFE-referral pattern is a specific concrete question that screens for treatment-philosophy match.

Iron-deficiency anemia from heavy fibroid bleeding is itself a health issue worth tracking. Our companion piece at `/articles/iron-deficiency-black-women-symptoms-screening-2026/` covers the ferritin screening test that many primary care visits skip, and pairs with this fibroid hub for readers whose fibroid bleeding is driving iron depletion.

Two things we do not know with confidence from the current literature:

First, we cannot tell you which specific biological factor drives the Black-white prevalence gap. Genetic variants, vitamin D, hormonal exposures, and environmental factors all show statistical association; no single factor is proven causal.

Second, we cannot tell you with certainty whether the hair-relaxer association with uterine cancer extends to a meaningful fibroid-growth effect. The cancer-side literature (Bertrand 2023 BWHS, the Sister Study) is more developed than the fibroid-specific literature on the same exposure. If you use chemical relaxers and have severe fibroid symptoms, that is a conversation to have with your OB-GYN; it is not a clear causal link in the published record.

If you have fibroid symptoms or a recent fibroid diagnosis:

1. Ask your OB-GYN or primary care clinician for an ultrasound or MRI to document size, number, and location if you have not had one in the last year. 2. Request a discussion of all treatment options including uterus-preserving procedures before any treatment plan is finalized. 3. If your plan skips to hysterectomy without the uterus-preserving options named, ask specifically about myomectomy and UFE and request a referral to an OB-GYN or interventional radiologist who performs them. 4. If you are trying to conceive, ask about fertility preservation options specifically. 5. Search the blackhealth.org directory for Black OB-GYNs in your metro; if your city has a gap, email the tips inbox via our contact form with specialty and metro and we will prioritize that geography in the next verification cycle.

Dr. Kendra Amari, DrPH, is Editor-in-Chief of blackhealth.org. This hub is a synthesis across our published reporting on uterine fibroids, updated as new supporting articles publish. Last reviewed 2026-04-24.

Supporting articles in this cluster: - Fibroids in Black women: the evidence on burden and treatment - The hysterectomy-vs-myomectomy treatment disparity - Uterine fibroid embolization (UFE) - UFE recovery time compared with surgical removal - Fibroids vs endometriosis: how to tell the difference - Do fibroids go away without surgery? - Fibroid symptoms: what is normal vs abnormal - Fibroids and fertility - Questions to ask your doctor about fibroids - Iron deficiency in Black women - Black maternal health hub